Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 5/20 | 0.39 |
| ▸ | FNTB | P49356 | 5/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | PTAFR | P25105 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAT2A | P31153 | 4/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29909732 | 0.93 | FNTA (0.39) | FNTAFNTBCNR1CNR2PTAFR | |
| SCHEMBL23576841 | 0.93 | FNTA (0.39) | FNTAFNTBCNR1CNR2PTAFR | |
| SCHEMBL29909526 | 0.90 | FNTA (0.39) | FNTAFNTBTP53MAPTMAT2A | |
| SCHEMBL23577383 | 0.90 | FNTA (0.39) | FNTAFNTBTP53MAPTMAT2A | |
| SCHEMBL23577059 | 0.89 | FNTA (0.41) | FNTAFNTBCNR1CNR2PTAFR | |
| SCHEMBL29909922 | 0.89 | FNTA (0.41) | FNTAFNTBCNR1CNR2PTAFR | |
| SCHEMBL23600551 | 0.85 | FNTA (0.40) | FNTAFNTBTP53MAPTMAT2A | |
| SCHEMBL23601743 | 0.85 | FNTA (0.39) | FNTAFNTBTP53MAPTMAT2A | |
| SCHEMBL23577102 | 0.84 | FNTA (0.41) | FNTAFNTBTP53MAPTMAT2A | |
| SCHEMBL23600548 | 0.84 | FNTA (0.40) | FNTAFNTBTP53MAPTMAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | FNTA 968/4885FNTB 743/4885CNR1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.